This mechanistic insight reveals a previously underappreciated axis in T cell biology and opens avenues for immunotherapy regimens targeting GluR-TCR interactions to augment T cell-mediated responses in cancer and potentially other immunopathologies.<h4>Video abstract</h4>. This evidence concerns the gene GSR and cancer.